Hong Kong (HSI) Pharma Industry Analysis

Industry Valuation and Performance

Has the Hong Kong Pharma Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Thu, 28 May 2026	HK$690.0b	HK$521.3b	HK$29.6b	14.3x	23.3x	1.3x
Sat, 25 Apr 2026	HK$771.7b	HK$517.7b	HK$29.9b	15x	25.8x	1.5x
Mon, 23 Mar 2026	HK$728.7b	HK$499.1b	HK$30.1b	11.8x	24.2x	1.5x
Wed, 18 Feb 2026	HK$825.2b	HK$497.2b	HK$30.5b	13.8x	27.1x	1.7x
Fri, 16 Jan 2026	HK$870.3b	HK$492.2b	HK$30.2b	13.4x	28.8x	1.8x
Sun, 14 Dec 2025	HK$835.2b	HK$485.6b	HK$29.8b	13.5x	28x	1.7x
Tue, 11 Nov 2025	HK$807.0b	HK$480.6b	HK$29.8b	14.1x	27x	1.7x
Thu, 09 Oct 2025	HK$843.1b	HK$479.7b	HK$30.6b	13.7x	27.5x	1.8x
Sat, 06 Sep 2025	HK$840.8b	HK$479.7b	HK$30.6b	13.9x	27.5x	1.8x
Mon, 04 Aug 2025	HK$745.3b	HK$473.3b	HK$29.0b	11.7x	25.7x	1.6x
Wed, 02 Jul 2025	HK$636.8b	HK$476.3b	HK$28.7b	11x	22.2x	1.3x
Fri, 30 May 2025	HK$589.1b	HK$477.8b	HK$28.9b	10.9x	20.4x	1.2x
Sun, 27 Apr 2025	HK$507.4b	HK$466.9b	HK$28.6b	10.6x	17.7x	1.1x
Tue, 25 Mar 2025	HK$470.7b	HK$466.1b	HK$31.8b	9.1x	14.8x	1x
Thu, 20 Feb 2025	HK$438.1b	HK$461.8b	HK$31.8b	8.5x	13.8x	0.9x
Sat, 18 Jan 2025	HK$401.9b	HK$459.4b	HK$31.7b	8.1x	12.7x	0.9x
Mon, 16 Dec 2024	HK$440.1b	HK$462.0b	HK$31.9b	8.3x	13.8x	1x
Wed, 13 Nov 2024	HK$442.0b	HK$464.7b	HK$32.3b	8.4x	13.7x	1x
Fri, 11 Oct 2024	HK$513.6b	HK$473.9b	HK$32.9b	7.9x	15.6x	1.1x
Sun, 08 Sep 2024	HK$438.9b	HK$474.5b	HK$32.9b	7.9x	13.3x	0.9x
Tue, 06 Aug 2024	HK$416.4b	HK$464.8b	HK$33.0b	7.3x	12.6x	0.9x
Thu, 04 Jul 2024	HK$438.1b	HK$461.1b	HK$33.7b	8.2x	13x	1x
Sat, 01 Jun 2024	HK$456.4b	HK$464.4b	HK$33.9b	8.2x	13.4x	1x
Mon, 29 Apr 2024	HK$459.0b	HK$463.7b	HK$33.8b	7.5x	13.6x	1x
Wed, 27 Mar 2024	HK$459.8b	HK$470.1b	HK$32.8b	7.8x	14x	1x
Fri, 23 Feb 2024	HK$448.9b	HK$471.0b	HK$33.6b	7.9x	13.4x	1x
Sun, 21 Jan 2024	HK$420.2b	HK$472.8b	HK$33.8b	6.9x	12.4x	0.9x
Tue, 19 Dec 2023	HK$479.5b	HK$472.3b	HK$33.8b	7.8x	14.2x	1x
Thu, 16 Nov 2023	HK$505.9b	HK$470.3b	HK$32.0b	7.1x	15.8x	1.1x
Sat, 14 Oct 2023	HK$442.5b	HK$469.3b	HK$31.5b	7.2x	14x	0.9x
Mon, 11 Sep 2023	HK$421.0b	HK$468.7b	HK$31.5b	6.8x	13.4x	0.9x
Wed, 09 Aug 2023	HK$440.0b	HK$445.6b	HK$27.8b	8.7x	15.8x	1x
Fri, 07 Jul 2023	HK$481.6b	HK$445.1b	HK$27.7b	9.5x	17.4x	1.1x
Sun, 04 Jun 2023	HK$511.9b	HK$449.2b	HK$28.0b	8.5x	18.3x	1.1x

Current Industry PE

Investors are optimistic on the Hong Kong Pharmaceuticals industry, and appear confident in long term growth rates.

The industry is trading at a PE ratio of 23.3x which is higher than its 3-year average PE of 18.2x.

The 3-year average PS ratio of 1.2x is lower than the industry's current PS ratio of 1.3x.

Past Earnings Growth

The earnings for companies in the Pharmaceuticals industry have remained mostly flat over the last three years.
Meanwhile revenues for these companies have grown 5.0% per year.
This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased and as a result, profits have held steady.

Industry Trends

Which industries have driven the changes within the Hong Kong Healthcare industry?


HK Market	-1.09%
Healthcare	-0.67%
Pharma	-1.97%
Pharma	-1.97%

Industry PEThere are no additional sub-industries under this industry.

Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
3692 Hansoh Pharmaceutical Group	HK$33.80	0.6% +HK$1.2b	31.8%	PE31.9x
2630 Vigonvita Life Sciences	HK$82.70	7.8% +HK$396.7m	n/a	PS46.8x
3933 United Laboratories International Holdings	HK$8.89	0.1% +HK$19.7m	-35.5%	PE7.3x
858 Extrawell Pharmaceutical Holdings	HK$0.077	5.5% +HK$11.6m	57.1%	PS4.2x

Company

Last Price

Valuation

3692 Hansoh Pharmaceutical Group

HK$33.80

0.6%
+HK$1.2b

31.8%

PE31.9x

2630 Vigonvita Life Sciences

HK$82.70

7.8%
+HK$396.7m

n/a

PS46.8x

3933 United Laboratories International Holdings

HK$8.89

0.1%
+HK$19.7m

-35.5%

PE7.3x

858 Extrawell Pharmaceutical Holdings

HK$0.077

5.5%
+HK$11.6m

57.1%

PS4.2x

Lanexa Biologics LLC Announces FDA Approval of LANGLARA an Interchangeable Biosimilar of Lantus

Lannett Company, Inc., Lanexa Biologics, a wholly owned subsidiary of Lannett, and Sunshine Lake Pharma announced that the U.S. Food and Drug Administration (FDA) has approved LANGLARA (insulin glargine-aldy), as a biosimilar to Lantus (insulin glargine), for the treatment of adults and pediatric patients with type 1 diabetes mellitus and adults with type 2 diabetes mellitus. The FDA has determined that LANGLARA is interchangeable with the reference drug, enabling pharmacists to substitute LANGLARA for Lantus without prescriber intervention in states that permit such substitution. The approval for LANGLARA was based on a comprehensive analytical, preclinical and clinical program which confirmed the PK/PD, efficacy, safety profile and immunogenicity of LANGLARA as compared to Lantus in patients with type 1 and type 2 diabetes. LANGLARA is manufactured by Sunshine Lake Pharma Co., Ltd., which is the pharmaceutical business arm of HEC Group and commercialized in the United States exclusively through Lanexa Biologics LLC, a newly formed wholly owned subsidiary of Lannett Company. FDA Biosimilar Interchangeability Designation: An interchangeable biosimilar is a biosimilar that may be substituted for the reference product without the intervention of the prescribing health care provider, depending on state pharmacy laws. Not all biosimilars are interchangeable biosimilars. A manufacturer must specifically seek FDA approval for an interchangeable product. The approval process for interchangeable biosimilars has additional requirements related to the potential for substitution. Patients receiving their medications through their pharmacies may be able to switch between a brand-name biological product and an interchangeable biosimilar. LANGLARA is manufactured by Sunshine Lake Pharma, a biopharmaceutical company with biologics manufacturing capabilities and a track record of regulatory compliance across international markets. The collaboration between Lannett and Sunshine Lake Pharma reflects a commitment to delivering high-quality, affordable biologic medicines to patients who need them. Sunshine Lake Pharma’s manufacturing facility has been designed and operated to meet the standards of both the FDA and international regulatory authorities, providing a robust and scalable supply chain for LANGLARA and future pipeline products. Lannett and Sunshine Lake Pharma also continue to collaborate on a short acting insulin aspart which is in development. Lanexa Biologics LLC is a wholly owned subsidiary of Lannett Company, Inc., established to serve as the commercial platform for Lannett’s biosimilar portfolio in the United States. Lanexa combines the distribution infrastructure, payer relationships, and regulatory expertise of its parent company with a dedicated focus on the unique commercial demands of the biologics market. The formation of Lanexa reflects Lannett’s commitment to biosimilars as a core growth driver and its belief that purpose-built commercial capabilities are essential to competing effectively in this space. LANGLARA is Lanexa’s inaugural insulin product. A short acting insulin aspart is also under development.

Hong Kong (HSI) Pharma Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Xuanzhu Biopharmaceutical Co., Ltd., Annual General Meeting, Jun 18, 2026

Analysts Just Made A Captivating Upgrade To Their CSPC Pharmaceutical Group Limited (HKG:1093) Forecasts

Sino Biopharmaceutical Signs Exclusive Deal With GSK to Bring New Hepatitis B Drug to China

United Laboratories Approved to Begin Trials of Once-Weekly Insulin Candidate in China

Executive Director exercised options and sold HK$16m worth of stock

Lanexa Biologics LLC Announces FDA Approval of LANGLARA an Interchangeable Biosimilar of Lantus

New minor risk - Dividend sustainability

There May Be Underlying Issues With The Quality Of Sihuan Pharmaceutical Holdings Group's (HKG:460) Earnings

Investor sentiment deteriorates as stock falls 17%

New minor risk - Shareholder dilution

Investor sentiment improves as stock rises 17%

Full year 2025 earnings released: CN¥2.33 loss per share (vs CN¥1.45 loss in FY 2024)